Microbiome-based diagnosis of pneumonia in the acute respiratory distress syndrome

基于微生物组的急性呼吸窘迫综合征肺炎诊断

• 批准号: 10321637
• 负责人: Georgios Kitsios
• 金额: $ 16.19万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-01-22 至 2022-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10321637
• 关键词: 16S ribosomal RNA sequencing; Accounting; Acute Lung Injury; Acute Respiratory Distress Syndrome; Address; Admission activity; Advisory Committees; Antibiotic Resistance; Antibiotics; Antimicrobial susceptibility; Bioinformatics; Caring; Categories; Clinical; Clinical Research; Clinical Trials; Clinical Trials Design; Communities; Computational Biology; Critical Care; Critical Illness; Culture Techniques; DNA; DNA analysis; DNA sequencing; Data; Development; Diagnosis; Diagnostic; Ecology; Etiology; Future; Genes; Goals; Hour; Hypersensitivity; Immune response; Individual; Infection; Inflammation; Inflammatory; Inflammatory Response; Infrastructure; Injury; Intensive Care Units; Interleukin-6; K-Series Research Career Programs; Laboratories; Lead; Lower respiratory tract structure; Lung; Mechanical ventilation; Medicine; Mentored Patient-Oriented Research Career Development Award; Mentors; Mentorship; Methods; Microbiology; Modernization; Organism; Pathogen detection; Patients; Pattern; Physicians; Pneumonia; Positioning Attribute; Prospective cohort study; Public Health; Regimen; Research; Research Design; Sampling; Scientist; Sensitivity and Specificity; Techniques; Time; Training; Universities; Validation; Work; accurate diagnosis; advanced analytics; antimicrobial; bacterial community; base; biobank; career development; clinical sequencing; cohort; cost effectiveness; design; diagnostic tool; effective therapy; effectiveness outcome; emerging antimicrobial resistance; experience; genome sequencing; human microbiota; improved; indexing; individual patient; infection management; inflammatory marker; innovation; lung injury; lung microbiome; microbial; microbial community; microbiome; microbiome research; microbiota; microbiota profiles; mortality; mortality risk; nanopore; next generation sequencing; novel; pathogen; personalized management; point of care; procalcitonin; prospective; receptor for advanced glycation endproducts; standard of care; technique development; training opportunity; translational physician; translational scientist; translational study; whole genome

PROJECT ABSTRACT This application is for a Mentored Patient-Oriented Research Career Development Award entitled “Microbiome-based diagnosis of pneumonia in the acute respiratory distress syndrome”. I am a Pulmonary and Critical Care Medicine Fellow at the University of Pittsburgh and I require additional training to develop expertise as a translational researcher in the microbiome of critical illness. The central objective of my research is to utilize emerging microbial DNA sequencing techniques for faster and more accurate diagnosis of pneumonia in critically-ill patients. The focus of my research is the acute respiratory distress syndrome (ARDS), a serious form of inflammatory lung injury often caused by pneumonia and accounting for 10% of intensive care unit admissions in the US with 40% mortality. With diagnostic limitations of the current standard- of-care of microbial cultures, patients often receive empiric, broad-spectrum antibiotics that can be inappropriate or inadequate for their individual needs, and also promote antibiotic resistance – a major public health threat. My preliminary data demonstrate feasibility and proof-of-concept that sequencing of microbial DNA directly from patient samples can lead to faster and more accurate diagnosis of pneumonia compared to cultures. The aims of the study are to develop sequencing-based definitions for pneumonia in (1) culture- positive and (2) culture-negative patients by integrating microbiome and host response data, and then 3) to assess the anticipated impact of sequencing on antibiotic selection. I will execute a prospective cohort study in patients with ARDS and use modern culture-independent sequencing techniques and computational biology methods to study the lung microbiome in relation to host-responses and microbiologic cultures. The proposed sequencing-based approach has the potential to improve accuracy of pneumonia diagnosis (capturing both cultivable and non-cultivable organisms) and to provide information to clinicians much faster than cultures. Thus, my proposal addresses a high priority issue for development of innovative diagnostics of infections to improve antibiotic usage and provides a unique translational training opportunity. I propose a research- intensive period of career development with hands-on and didactic training in advanced sequencing techniques, bioinformatics, computational biology and clinical trial design and implementation. The work will be conducted within the Division of Pulmonary, Allergy, and Critical Care Medicine at the University of Pittsburgh, which has an outstanding record of training physician-scientists and a highly-developed infrastructure for the conduct of translational studies. I am supported by a committed mentoring partnership with convergent expertise in microbiome and critical care research, and a diverse Mentoring Advisory Committee. With support from the K23 Mentored Career Development Award, I will develop an independent project examining sequencing-based pneumonia diagnostics for an R01 proposal over the next five years.

项目摘要 本申请是一个指导病人为导向的研究职业发展奖， 急性呼吸窘迫综合征患者肺炎的微生物群诊断我是一个 匹兹堡大学的肺和重症监护医学研究员和我需要额外的培训， 发展作为危重疾病微生物组转化研究员的专业知识。我的中心目标是 研究是利用新兴的微生物DNA测序技术，更快，更准确地诊断 重症患者的肺炎。我的研究重点是急性呼吸窘迫综合征 急性呼吸窘迫综合征（ARDS）是一种严重的炎性肺损伤，通常由肺炎引起，占 重症监护病房入院率高达40%。现有标准的诊断局限性- 在微生物培养的护理中，患者经常接受经验性的广谱抗生素， 不适合或不足以满足他们的个人需求，也促进抗生素耐药性-一个主要的公众 健康威胁。我的初步数据证明了微生物测序的可行性和概念验证。 直接从患者样本中提取的DNA可以更快、更准确地诊断肺炎， cultures.该研究的目的是开发基于测序的肺炎定义（1）文化- 通过整合微生物组和宿主反应数据，对（2）培养阴性患者进行检测，然后3） 评估测序对抗生素选择的预期影响。我将进行一项前瞻性队列研究， 并使用现代非培养测序技术和计算生物学 研究与宿主反应和微生物培养物相关的肺微生物组的方法。拟议 基于测序的方法有可能提高肺炎诊断的准确性（捕获两者）。 可培养的和不可培养的生物体），并比培养更快地向临床医生提供信息。 因此，我的建议解决了一个高度优先的问题，即开发创新的感染诊断方法， 改善抗生素的使用，并提供独特的翻译培训机会。我提议做一项研究- 职业发展的密集期，在高级排序中进行实践和教学培训 技术，生物信息学，计算生物学和临床试验设计和实施。这项工作将 在匹兹堡大学肺、过敏和重症监护医学部进行， 它在培训医学科学家和高度发达的基础设施方面有着出色的记录， 进行翻译研究。我得到了一个致力于指导合作伙伴关系的支持， 微生物组和重症监护研究方面的专业知识，以及多元化的指导咨询委员会。支持下 从K23指导职业发展奖，我将开发一个独立的项目， 在未来五年内为R 01提案提供基于测序的肺炎诊断。

项目成果

Inter-rater reliability and prognostic value of baseline Radiographic Assessment of Lung Edema (RALE) scores in observational cohort studies of inpatients with COVID-19.

• DOI: 10.1136/bmjopen-2022-066626
• 发表时间: 2023-01-12
• 期刊: BMJ open
• 影响因子: 2.9

Protecting the lungs but hurting the kidneys: causal inference study for the risk of ventilation-induced kidney injury in ARDS.

保护肺部但伤害肾脏：ARDS 通气诱发肾损伤风险的因果推断研究。

• DOI: 10.21037/atm-20-2050
• 发表时间: 2020
• 期刊: Annals of translational medicine
• 作者: Yang,Haopu;Benos,PanayiotisV;Kitsios,GeorgiosD
• 通讯作者: Kitsios,GeorgiosD

A Pilot Double-Blind Placebo-Controlled Randomized Clinical Trial to Investigate the Effects of Early Enteral Nutrients in Sepsis.

• DOI: 10.1097/cce.0000000000000550
• 发表时间: 2021-10
• 期刊: Critical care explorations
• 作者: Shah FA;Kitsios GD;Yende S;Dunlap DG;Scholl D;Chuan B;Al-Yousif N;Zhang Y;Nouraie SM;Morris A;Huang DT;O'Donnell CP;McVerry BJ
• 通讯作者: McVerry BJ

Protein arginine N-methyltransferase 4 (PRMT4) contributes to lymphopenia in experimental sepsis.

• DOI: 10.1136/thoraxjnl-2021-217526
• 发表时间: 2023-04
• 期刊: Thorax
• 影响因子: 10

Association of the systemic host immune response with acute hyperglycemia in mechanically ventilated septic patients.

• DOI: 10.1371/journal.pone.0248853
• 发表时间: 2021
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Farooq N;Chuan B;Mahmud H;El Khoudary SR;Nouraie SM;Evankovich J;Yang L;Dunlap D;Bain W;Kitsios G;Zhang Y;O'Donnell CP;McVerry BJ;Shah FA
• 通讯作者: Shah FA